What is Immunic?
Immunic is a biotherapeutic organization that historically focused on the development of cell-based therapies, most notably the ELAD System, a bio-artificial liver designed to treat acute liver failure. The company's market position was defined by its commitment to addressing high-unmet medical needs through advanced clinical testing and pilot manufacturing. Following the results of its Phase 3 clinical trials, which did not achieve the required statistical significance for regulatory approval, the company underwent a significant strategic shift. Currently, Immunic is focused on the preservation of value through the potential divestiture of its intellectual property and assets, moving away from active clinical development to maximize returns for stakeholders.
How much funding has Immunic raised?
Immunic has raised a total of $63.7M across 3 funding rounds:
Series A
$19.7M
Share Placement
$15M
Debt
$29M
Series A (2016): $19.7M with participation from High-Tech Gru00fcnderfonds, Life Sciences Partners, LifeCarePartners, and Bayern Kapital
Share Placement (2020): $15M led by Altium Capital Limited
Debt (2020): $29M supported by The European Investment Bank
Key Investors in Immunic
The European Investment Bank
Established in 1958 and headquartered in Luxembourg, European Investment Bank (EIB) is the European Union's nonprofit long-term lending and finance institution.
Life Sciences Partners
A prominent European venture capital firm that focuses on life sciences, providing strategic backing to companies at various stages of development.
Bayern Kapital
Bayern Kapital is a leading venture capital investor in Bavaria, focusing on innovative, technology-oriented startups and companies across various sectors including High-Tech, DeepTech, and Life Sciences.
What's next for Immunic?
The future of Immunic is centered on the execution of strategic alternatives, including the potential sale of company assets and intellectual property. Given the cessation of development for the ELAD System and the subsequent reduction in workforce, the company's primary objective is to navigate the liquidation or transfer of its remaining technological portfolio. This phase requires careful management of existing capital resources to ensure that the firm can fulfill its obligations while exploring opportunities for asset monetization. Investors and stakeholders are now focused on the efficiency of this wind-down process and the potential for recovering value from the company's historical research and development efforts.
See full Immunic company page
